Nuclear Medicine Imaging of Prostate Cancer

Schreiter, Vera; Reimann, Carolin; Geisel, Dominik; Schreiter, Nils

doi:10.1055/s-0042-108860

Cited by 11 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Location of primary tumor and initial staging of the disease are critical for treatment planning. As a consequence, a variety of imaging modalities have been tried out for the evaluation of patients with PCa in primary and also secondary staging . European Association of Urology (EAU) guidelines recommend at least one cross‐sectional imaging study (computed tomography [CT] or magnetic resonance imaging [MRI]) of the abdomen and pelvis along with bone scintigraphy (BS) for metastasis screening in intermediate‐to‐high‐risk primary PCa .…”

Section: Introductionmentioning

confidence: 99%

Comparison of preoperative locoregional Ga‐68 PSMA‐11 PET‐CT and mp‐MRI results with postoperative histopathology of prostate cancer

Yılmaz¹,

Türkay

Çolakoğlu

et al. 2019

The Prostate

View full text Add to dashboard Cite

Background: Conventional imaging modalities are inadequate to evaluate locoregional extension of prostate cancer (PCa). The aim of the current retrospective study was to investigate the diagnostic efficacy of Gallium-68 prostate-specific membrane antigen-11 (Ga-68 PSMA-11) positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance imaging (mp-MRI) for staging preoperative PCa patients with correlating histopathology. Materials and Methods:Twenty-four patients with histologically proven PCa underwent both Ga-68 PSMA-11 PET/CT and mp-MRI before robot-assisted laparoscopic radical prostatectomy. For each tumor area, correlations with histopathological results were defined for tumor localization, extraprostatic extension (EPE) of the tumor, invasion of seminal vesicle (SVI) and bladder neck invasion (BNI). In patients with regional lymph node (LN) dissection, histopathological results were also correlated with imaging modalities.Results: Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detection of EPE and SVI were higher for mp-MRI than Ga-68 PSMA-11 PET/CT. On the other hand Ga-68 PSMA-11 PET/CT had significant successful results for detection of LN metastases when compared with mp-MRI. But for BNI detection both modalities had same insufficient results. Ga-68 PSMA-11 PET/ CT had strong results for appropriate tumor localization in the gland. Conclusion: Ga-68 PSMA PET/CT has superior results for assessing local LN metastases and for intraprostatic tumor localization. Whereas, mp-MRI must be the preferred modality for determining SVI and EPE. But both imaging modalities failed for determining BNI accurately. Both modalities should be used in conjunction with each other for better treatment planning. K E Y W O R D S extraprostatic extension, Gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography, lymph node, multiparametric magnetic resonance imaging, prostate cancer, seminal vesicle The Prostate. 2019;79:1007-1017. wileyonlinelibrary.com/journal/pros

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of preoperative locoregional Ga‐68 PSMA‐11 PET‐CT and mp‐MRI results with postoperative histopathology of prostate cancer

Yılmaz¹,

Türkay

Çolakoğlu

et al. 2019

The Prostate

View full text Add to dashboard Cite

show abstract

“…This is particularly evident in tissue areas with low oxygen levels. The study conducted by Weeks et al [ 79 ] examined the amount of internalization of [ 64 Cu]-diacetyl-bis (N(4)-methylthiosemicarbazone) ([ 64 Cu]-ATSM) in breast cancer cells under hypoxic conditions, and the possible therapeutic effect of this compound. Various doses of [ 64 Cu]-ATSM, up to a maximum of 10 MBq/mL, were administered to the MCF-7 cell line in these studies.…”

Section: Validation Of Radiopharmaceuticals In Vitro By γ-Countermentioning

confidence: 99%

An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics

et al. 2023

View full text Add to dashboard Cite

Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ) radiation through radiation decay. Therefore, they are used in the biomedical field to label biomolecules or drugs for diagnostic imaging applications, such as positron emission tomography (PET) and/or single-photon emission computed tomography (SPECT). A growing field of research is the development of new radiopharmaceuticals for use in cancer treatments. Preclinical studies are the gold standard for translational research. Specifically, in vitro radiopharmaceutical studies are based on the use of radiopharmaceuticals directly on cells. To date, radiometric β- and γ-counters are the only tools able to assess a preclinical in vitro assay with the aim of estimating uptake, retention, and release parameters, including time- and dose-dependent cytotoxicity and kinetic parameters. This review has been designed for researchers, such as biologists and biotechnologists, who would like to approach the radiobiology field and conduct in vitro assays for cellular radioactivity evaluations using radiometric counters. To demonstrate the importance of in vitro radiopharmaceutical assays using radiometric counters with a view to radiogenomics, many studies based on 64Cu-, 68Ga-, 125I-, and 99mTc-labeled radiopharmaceuticals have been revised and summarized in this manuscript.

show abstract

“…9 A substantial number of patients classified as having nonmetastatic disease on conventional imaging would be reclassified as having metastatic disease if a more sensitive imaging technique were used. 10,11 Second, life expectancy based on age and comorbidities should also be taken into account when managing patients with high-risk nonmetastatic disease. 12 Third, biopsy Gleason sum, PSA level, extracapsular extension, positive surgical margin upon resection, seminal vesicle invasion and lymph node status are the most important adverse prognostic factors that would dictate the choice of therapy.…”

Section: Management Of Non-metastatic High Risk Patientsmentioning

confidence: 99%

Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence

Aoun

Bourgi

Ayoub

et al. 2017

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Abstract:Following new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice for those patients. These variables are summarized and discussed in detail. High radiation doses to the prostate are essential to achieve good local control in patients with high-risk nonmetastatic disease. Addition of androgen deprivation therapy (ADT) to radiation therapy has significantly improved overall survival and cancer-specific survival compared with radiation therapy alone without significantly increasing toxicity. Long-term neo(adjuvant) ADT (2-3 years) to radiation therapy significantly improved cancer-specific survival compared with short-term ADT (4-6 months). Radical prostatectomy with extended pelvic lymph node dissection is considered a reasonable option in experienced hands. ADT alone is an inappropriate treatment option for patients with high-risk nonmetastatic disease. Management decisions for these patients should be discussed by a multidisciplinary team.

show abstract

Nuclear Medicine Imaging of Prostate Cancer

Cited by 11 publications

References 32 publications

Comparison of preoperative locoregional Ga‐68 PSMA‐11 PET‐CT and mp‐MRI results with postoperative histopathology of prostate cancer

Comparison of preoperative locoregional Ga‐68 PSMA‐11 PET‐CT and mp‐MRI results with postoperative histopathology of prostate cancer

An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics

Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence

Contact Info

Product

Resources

About